Nautilus Biotechnology Inc at Morgan Stanley Global Healthcare Conference Transcript
Hey, everyone. Good morning. My name is Tejas Savant. I know lot of you in the room. I cover Life Science Tools and Diagnostics sector here at Morgan Stanley. Before we get started, I just want to read the disclosure statement. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your sales rep. It's my pleasure this morning to host Nautilus and speaking on behalf of the company, we have Sujal Patel, CEO. Thanks, Sujal, for joining us today.
Maybe just to set the stage, for folks you're in on the webcast, not as familiar with Nautilus, could you just give a brief history of how the company came into being. And where do you see Nautilus fitting in the evolving Proteomics landscape?
Questions & Answers
Great. Well, just let me start by thanking you and Morgan Stanley for the invite to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |